Search
Exemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalExemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal … It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
Products: EXEMESTANE DOC GENERICI, EXEMESTANE MYLAN GENERICSMagaldrate
go.drugbank.com/drugs/DB08938ApprovedInvestigationalWithdrawnMagaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Mixtures: M A L D I M, RIOPAN GEL MAGALDRATO/DIMETICONAProducts: MAGALDRATO SPECIAL PRODUCT'S LINE, RIOPAN MAGEN GEL STICK PACGlatiramer
go.drugbank.com/drugs/DB05259ApprovedInvestigational[A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … [A248870] Along with [human interferon beta], [teriflunomide], and [dimethyl fumarate], glatiramer acetate is a first-line drug for patients with MS.
Synonyms: Copolymer I (synthetic peptide)Products: Copaxone 20 mg/ml Injektionslösung in einer Fertigspritze, Copaxone 40 mg/ml Injektionslösung in einer FertigspritzeGliclazide
go.drugbank.com/drugs/DB01120ApprovedInvestigationalMedications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. … The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals.
Categories: Drugs Used in DiabetesProducts: Gliavis IR Tablet 80mg, GLICLAZIDE GENTIAN GENERICSBisacodyl
go.drugbank.com/drugs/DB09020ApprovedInvestigationalBisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation. … [A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956[L33045] but has been used as a laxative since 1952.[A233300]
Mixtures: Bi-peglyteProducts: LERLEZ ® 5MG TABLETAS DE LIBERACION RETARDADA., EVAXFEM® 5 MG TABLETAS DE LIBERACIÓN RETARDADAMavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalIt received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).
Products: CAMZYOS® 2.5MG CAPSULAS DURAS DE LIBERACIÓN INMEDIATA.Potassium citrate
go.drugbank.com/drugs/DB09125ApprovedInvestigationalVet approvedIt contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. … Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste.
Mixtures: Calcium-magnesium With K & Zn and Vitamin D3, PEDIALYTE®30MEQ CON ZNProducts: UROCIT-K® 10 MEQ TABLETAS DE LIBERACION PROLONGADARisankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. … Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23).
Products: SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML, SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.83MLNorepinephrine
go.drugbank.com/drugs/DB00368ApprovedInvestigationalIt is also found in plants and is used pharmacologically as a sympathomimetic. … Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus.
Products: Norepinephrine Bitartrate In Sodium Chloride, Norepinephrine Bitartrate In 5% Dextrose InjectionIvabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalIvabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate … Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the
Products: IVABRADINA DOC GENERICI, Ivabradin Genericon 2,5 mg Filmtabletten